Internal Reference Number: FOI_6335
Date Request Received: 21/10/2021 00:00:00
Date Request Replied To: 17/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer Treatment
Request Category: Companies
Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below? • Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent • Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Carboplatin or Cisplatin as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fluorouracil • Fulvestrant as a single agent • Goserelin • Lapatinib • Neratinib • Olaparib • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pertuzumab + Trastuzumab + Docetaxel • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Talazoparib • Tamoxifen • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Transtuzumab as a single agent • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
Answer To Question 1: Aromatase inhibitor- unable to respond as could be provided via multiple routes Abemaciclib +AI- 1 Abemaciclb+ fulvestrant- 2 Anthracycline single agent- 0 Atezolizumab + Nab-paclitaxel- 4 Capecitabine single agent- 21 Carboplatin/cisplatin and Platinum single agent- 0 Eribulin- 0 Everolimus + exemestane- 0 Fluorouracil-0 Fulvestrant single agent-4 Goserilin- unable to answer as multiple routes of supply and stock on some areas Lapatinib-0 Netatinib-1 Olaparib- 0 Palbociclib+AI- 33 Palbociclib +fulvestrant- 3 Pertuzumab+Trastuzumab+docetaxel- 6 Ribociclib (both options)- 0 Talazoparib-0 Tamoxifen- unable to respond as could be provided via multiple routes Taxane- 12 Trastuzumab single agent- 9 Trastuzumab emtansine-5 Trastuzumab deruxtecan-0 Any other- 195 patient episodes, number of individual patients not recorded. | |
Question Number 2: In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent? | |
Answer To Question 2: Unable to answer as the reports do not list the staging | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.